|
|
News Breaks | | | | February 4, 2013 | | 17:37 EDT |  | OGXI | OncoGenex CFO Michelle Burris resigns from position, to leave company March 31
OncoGenex disclosed in a regulatory filing that in early January, Scott Cormack, president and CEO, and Michelle Burris, executive VP of operations, CFO, principal accounting officer, treasurer and secretary, disclosed to the company’s board that they have a developing personal relationship with one another that warranted consideration of their reporting relationship and duties. After consideration and discussion by the independent members of the company’s board, as well as consultations with Cormack and Burris, the company’s board determined that it would be advisable for Burris to transfer her executive duties to others and to continue portions of her work in operations as a consultant to the company, reporting directly to the board. On February 1 Burris resigned as the company’s principal accounting officer, CFO, secretary and treasurer. From February 1 to March 31, Burris will continue to serve as the company’s executive VP of operations. Effective March 31, Burris will resign as the company’s executive VP of operations, and the company has agreed to pay all wages, bonuses, vacation, reimbursable expenses and similar payments due to Burris as of such date. On January 31 the company’s board appointed Cormack as the company’s principal financial officer, secretary and treasurer and Susan Wyrick as the company’s principal accounting officer, effective February 1. | |
|
News For OGXI From The Last 14 Days Check below for free stories on OGXI the last two weeks. |
|
|
| May 23, 2013 | | 07:12 EDT | | OGXI | OncoGenex plans initiation of Ceder clinical trial for OGX-427
OncoGenex Pharmaceuticals announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer. This trial will be the seventh randomized Phase 2 clinical trial evaluating OGX-427 in the treatment of advanced cancers and will investigate whether adding OGX-427 to gemcitabine and carboplatin therapy can extend progression-free survival, or PFS, outcomes. Cedar will randomize approximately 140 patients to receive either OGX-427 plus gemcitabine and carboplatin therapy, or gemcitabine and carboplatin therapy alone. The primary objective will be PFS, with secondary objectives to evaluate tumor response rates, overall survival, safety, tolerability, and health-related quality of life. Additional analyses will be conducted to determine the effect of therapy on heat shock protein 27 levels and to explore potential biomarkers that may help predict response to treatment. | | | May 22, 2013 | | 07:35 EDT |  | OGXI | Bloom Burton & Co. to host a conference
 Subscribe for More Information | |
|
|
|
|
|
|
